Wall Street analysts expect KemPharm, Inc. (NASDAQ:KMPH – Get Rating) to report ($0.14) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts released earnings estimates for KemPharm, with the highest EPS estimate of $0.12 and the lowest estimate of $0.16. KemPharm reported earnings per share of ($0.40) in the same quarter last year, suggesting a positive growth rate of 65% year over year. The company is expected to announce its next quarterly earnings report on Monday, January 1.
According to Zacks, analysts expect KemPharm to report annual earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.42) to ($0.12). $). For the next fiscal year, analysts expect the company to post earnings of $0.25 per share, with EPS estimates ranging from ($0.09) to $0.59. Zacks Investment Research EPS averages are an average based on a survey of sell-side research analysts who track KemPharm.
KemPharm (NASDAQ:KMPH – Get Rating) last released quarterly earnings data on Wednesday, March 30. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). KemPharm had a negative net margin of 0.60% and a negative return on equity of 0.28%.
Several research companies have commented on KMPH. StockNews.com began covering KemPharm shares in a research report on Thursday, March 31. They issued a “hold” rating for the company. Zacks Investment Research upgraded KemPharm shares from a “sell” rating to a “hold” rating in a Tuesday, May 24 research report.
KemPharm shares opened Wednesday at $4.63. KemPharm has a 12-month low of $4.00 and a 12-month high of $15.70. The company’s 50-day moving average price is $4.65 and its two-hundred-day moving average price is $6.32.
Several hedge funds and other institutional investors have been buying and selling stocks recently. BlackRock Inc. increased its stake in KemPharm shares by 0.8% in the 1st quarter. BlackRock Inc. now owns 2,253,334 shares of the specialty pharmaceutical company worth $11,333,000 after purchasing an additional 17,792 shares during the period. Vanguard Group Inc. increased its stake in KemPharm shares by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 1,516,912 shares of the specialty pharmaceutical company worth $7,630,000 after purchasing 33,367 additional shares during the period. State Street Corp increased its stake in KemPharm shares by 2.4% in the 1st quarter. State Street Corp now owns 551,615 shares of the specialty pharmaceutical company worth $2,775,000 after purchasing an additional 12,798 shares during the period. Geode Capital Management LLC increased its stake in KemPharm shares by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 505,527 shares of the specialty pharmaceutical company worth $4,403,000 after purchasing an additional 16,795 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in KemPharm shares by 2.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 285,915 shares of the specialty pharmaceutical company worth $2,490,000 after purchasing an additional 6,475 shares during the period. 32.39% of the shares are held by institutional investors and hedge funds.
About KemPharm (Get a rating)
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The Company uses its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
Get a Free Copy of Zacks Research Report on KemPharm (KMPH)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in KemPharm right now?
Before you consider KemPharm, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and KemPharm wasn’t on the list.
While KemPharm currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here